Should gonadotropin releasing hormone analogue be administered to prevent premature ovarian failure in young women with systemic lupus erythematosus on cyclophosphamide therapy?
Sinha
Rajiv
R
Paediatric Nephrology, British Columbia's Children's Hospital, Vancouver, BC, Canada. rajivsinha_in@yahoo.com
Dionne
Janis M
JM
D058186:Acute Kidney Injury / Q000150:complications; D000293:Adolescent; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects; D003520:Cyclophosphamide / Q000009:adverse effects; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000627:therapeutic use*; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D016649:Primary Ovarian Insufficiency / Q000139:chemically induced / Q000517:prevention & control*
D018906:Antineoplastic Agents, Alkylating; D007987:Gonadotropin-Releasing Hormone; D003520:Cyclophosphamide